Barron takes on business development role

Eurofins AvTech Laboratories has appointed Michael Barron as director of business development.

Eurofins AvTech Laboratories, a US analytical contract research organisation (CRO), has appointed Michael Barron as director of business development.

Barron has previously worked for Catalent Pharma Solutions, Cardinal Health, and other leading contract drug development and analytical service companies.

AvTech offers analytical support for all stages of drug discovery and development from early ADME studies of drug candidates to stability and release testing of the finished product. The company places particular emphasis on the development, validation, and routine performance of GMP and GLP compliant methods.




You may also like

Research & Development

BioGenes and Eurofins Munich form HCP analysis partnership

BioGenes specialises in highly sophisticated and customized antibody and immunoassay development
Research & Development

Merck Millipore to sell Discovery and Development Solutions Business to Eurofins

DDS provides bioanalytical testing and early stage discovery services to the biopharmaceutical market
Regulatory

BetaGlue Therapeutics gains MHRA approval for pancreatic cancer trial

YntraDose, the innovative radiotherapy treatment for unresectable locally advanced pancreatic cancer, has been granted an early feasibility clinical investigation and will assess safety and performance in patients
Research & Development

Scottish immunology CRO RoukenBio celebrates 10 years of growth

Formerly known as Antibody Analytics, the contract research organisation has grown from three employees to over 100 and enjoyed successes such as the launch of its first proprietary technology, IndEx-2 and multi-million pound investments
Manufacturing

Abzena advances ADC development with ThioBridge conjugation technology

Next-generation conjugation delivers greater stability, potency and control for targeted cancer therapeutics
Research & Development

DBV Technologies announces last patient visit completed in Phase III peanut allergy trial in children

The Phase III VITESSE clinical trial of the VIASKIN Peanut patch in peanut allergic children aged 4-7 years remains on track for topline data in Q4 of this year
Research & Development

Medicines Discovery Catapult announces collaboration with £15.9m project on next-gen human disease modelling

The Medical Research Council, Wellcome Trust and Innovate UK will work with MDC to develop advanced, specific and highly reproducible human-based in vitro models of disease, with the aim of making them widely available to researchers in academia and industry
Subscribe now